Medicenna Therapeutics Corp.

Medicenna Therapeutics Corp. Stock Forecast & Price Prediction

Live Medicenna Therapeutics Corp. Stock (MDNAF) Price
$1.70

0

Ratings

  • Buy 0
  • Hold 0
  • Sell 0
Disclaimer : Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance. This information is for educational purposes only and should not be construed as advice to buy or sell any security.

Stock Price

$1.70

P/E Ratio

-4.65

Volume Traded Today

$6,400

Dividend

Dividends not available for MDNAF

52 Week High/low

2.20/0.30

Medicenna Therapeutics Corp. Market Cap

$133.2M

๐Ÿ›‘ Alert: These ten stocks could have higher potential than $MDNAF ๐Ÿ›‘

Before you buy MDNAF you'll want to see this list of ten stocks that have huge potential. Want to see if MDNAF made the cut? Enter your email below

MDNAF Summary

From what 0 stock analysts predict, the share price for Medicenna Therapeutics Corp. (MDNAF) might increase by 6.75% in the next year. This is based on a 12-month average estimation for MDNAF. Price targets go from $1.81479 to $1.81479. The majority of stock analysts believe MDNAF is a sell. Please note analyst price targets are not guaranteed and could be missed completely.

MDNAF Analyst Ratings

MDNAF is a stock in Healthcare which has been forecasted to be worth $1.81479 as an average. On the higher end, the forecast price is $1.81479 USD by from and on the lower end MDNAF is forecasted to be $1.81479 by from .

MDNAF stock forecast by analyst

These are the latest 20 analyst ratings of MDNAF.

Analyst/Firm

Rating

Price Target

Change

Date


Oppenheimer

Outperform


Initiates

Dec 18, 2020

Oppenheimer

Outperform


Initiates

Dec 17, 2020

HC Wainwright & Co.

Buy


Initiates

Sep 10, 2020

MDNAF Company Information

What They Do: Develops immunotherapies for cancer treatment.

Business Model: Medicenna Therapeutics Corp. focuses on the development and commercialization of innovative immunotherapies known as Superkines. The company generates revenue through the research, development, and potential commercialization of its proprietary drug candidates designed to treat various cancers and autoimmune diseases.

Other Information: Medicenna's pipeline includes several advanced therapeutic candidates targeting recurrent glioblastoma and other tumors, as well as autoimmune conditions. The company also leverages its BiSKITs platform to create customized Superkines, enhancing its research capabilities and product offerings. Headquartered in Toronto, Canada, Medicenna is positioned in a growing sector with significant potential for impact on cancer treatment.
MDNAF
Medicenna Therapeutics Corp. (MDNAF)

When did it IPO

2017

Staff Count

16

Country

Canada

Sector/Industry

Healthcare/Biotechnology

CEO

Dr. Fahar Merchant Ph.D.

Market Cap

$133.2M

Medicenna Therapeutics Corp. (MDNAF) Financial Data

In 2023, MDNAF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MDNAF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2020

N/A

Revenue From 2021

$0

0.00 %
From Previous Year

Revenue From 2022

$0

0.00 %
From Previous Year

Revenue From 2023

$0

0.00 %
From Previous Year
  • Revenue TTM $0
  • Operating Margin TTM 0.0%
  • Gross profit TTM $0
  • Return on assets TTM -32.8%
  • Return on equity TTM -105.4%
  • Profit Margin 0.0%
  • Book Value Per Share 0.30%
  • Market capitalisation $133.2M
  • Revenue for 2021 $0
  • Revenue for 2022 $0
  • Revenue for 2023 $0
  • EPS this year (TTM) $-0.27

Medicenna Therapeutics Corp. (MDNAF) Latest News

News Image

Fri, 04 Oct 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Updated clinical results from the Phase 1/2 ABILITY-1 study of MDNA11 in advanced or metastatic solid tumors will be presented soon.

Why It Matters - Updated clinical results may indicate the efficacy and safety of MDNA11, influencing investor sentiment and stock performance for the company involved in cancer treatment.

News Image

Thu, 26 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Medicenna Therapeutics Corp. (TSX: MDNA, OTCQB: MDNAF) announced the voting results from its annual shareholder meeting held on September 26, 2024.

Why It Matters - Voting results from Medicenna's annual meeting can indicate shareholder confidence and strategic direction, impacting stock performance and market sentiment.

News Image

Mon, 09 Sep 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - MDNA209, a first-in-class IL-2 Super-antagonist, is being developed for autoimmune diseases, which affect 5-10% of the global population.

Why It Matters - MDNA209's development signals potential market opportunities in autoimmune treatments, impacting stock valuations and investor interest in biotech firms focused on innovative therapies.

News Image

Thu, 15 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - Medicenna Therapeutics appointed Mr. Karim Lalji to its Board of Directors effective August 14, 2024. The company focuses on developing Superkines in immunotherapy.

Why It Matters - The appointment of Karim Lalji to Medicenna's Board may signal strategic shifts or new expertise, potentially impacting company direction and investor confidence in its growth prospects.

News Image

Thu, 01 Aug 2024

Sentiment - NEUTRAL

Source - GlobeNewsWire

Summary - A melanoma patient achieved complete response after 52 weeks of MDNA11 treatment, with 100% regression of lesions, highlighting its potential as a leading therapy.

Why It Matters - The successful treatment of melanoma with MDNA11 highlights its strong efficacy, potentially positioning the company as a leader in oncology, which could drive stock value and investor interest.

News Image

Mon, 22 Jul 2024

Sentiment - NEUTRAL

Source - Seeking Alpha

Summary - Medicenna Therapeutics focuses on engineered interleukins for oncology. Key products MDNA11 and Bizaxofusp show promise in trials, but recent Nasdaq delisting poses liquidity challenges.

Why It Matters - Medicenna's clinical advancements in oncology could drive future revenue, but Nasdaq delisting raises concerns over liquidity and funding, impacting long-term viability and stock performance.

...

MDNAF Frequently asked questions

The highest forecasted price for MDNAF is $1.81479 from at .

The lowest forecasted price for MDNAF is $1.81479 from from

The MDNAF analyst ratings consensus are 0 buy ratings, 0 hold ratings, and 0 sell ratings.